HRP20090680T1 - Formulacija s modificiranim otpuštanjem 1-/(3-hidroksi-adamant-1-ilamino)-acetil/-pirolidin-2-(s)-karbonitrila - Google Patents
Formulacija s modificiranim otpuštanjem 1-/(3-hidroksi-adamant-1-ilamino)-acetil/-pirolidin-2-(s)-karbonitrila Download PDFInfo
- Publication number
- HRP20090680T1 HRP20090680T1 HR20090680T HRP20090680T HRP20090680T1 HR P20090680 T1 HRP20090680 T1 HR P20090680T1 HR 20090680 T HR20090680 T HR 20090680T HR P20090680 T HRP20090680 T HR P20090680T HR P20090680 T1 HRP20090680 T1 HR P20090680T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- patient
- vildagliptin
- day
- pharmaceutically acceptable
- Prior art date
Links
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 title claims abstract 84
- 238000009472 formulation Methods 0.000 title claims 9
- 239000000203 mixture Substances 0.000 title claims 9
- 239000002552 dosage form Substances 0.000 claims abstract 130
- 229960001254 vildagliptin Drugs 0.000 claims abstract 83
- 150000003839 salts Chemical class 0.000 claims abstract 45
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 12
- 239000004615 ingredient Substances 0.000 claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- 239000000945 filler Substances 0.000 claims abstract 4
- 239000000314 lubricant Substances 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims 43
- 239000012458 free base Substances 0.000 claims 36
- 239000006186 oral dosage form Substances 0.000 claims 30
- 239000002585 base Substances 0.000 claims 26
- 239000003826 tablet Substances 0.000 claims 25
- 235000020937 fasting conditions Nutrition 0.000 claims 24
- 239000007916 tablet composition Substances 0.000 claims 21
- 235000021152 breakfast Nutrition 0.000 claims 12
- 238000000034 method Methods 0.000 claims 9
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 7
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 6
- 239000012730 sustained-release form Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 4
- 239000007891 compressed tablet Substances 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 4
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 229960005095 pioglitazone Drugs 0.000 claims 2
- 229960004586 rosiglitazone Drugs 0.000 claims 2
- -1 3-hydroxy-1-adamantyl Chemical group 0.000 claims 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 238000005056 compaction Methods 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000009490 roller compaction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68971905P | 2005-06-10 | 2005-06-10 | |
| US69030905P | 2005-06-14 | 2005-06-14 | |
| PCT/US2006/022416 WO2006135723A2 (en) | 2005-06-10 | 2006-06-08 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090680T1 true HRP20090680T1 (hr) | 2010-02-28 |
Family
ID=37532821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090680T HRP20090680T1 (hr) | 2005-06-10 | 2009-12-21 | Formulacija s modificiranim otpuštanjem 1-/(3-hidroksi-adamant-1-ilamino)-acetil/-pirolidin-2-(s)-karbonitrila |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20100021539A1 (es) |
| EP (2) | EP1898904B1 (es) |
| JP (7) | JP5579986B2 (es) |
| KR (1) | KR101312812B1 (es) |
| AR (1) | AR054383A1 (es) |
| AT (2) | ATE444748T1 (es) |
| AU (1) | AU2006257947B2 (es) |
| BR (1) | BRPI0613499B8 (es) |
| CA (1) | CA2610422A1 (es) |
| CY (1) | CY1109719T1 (es) |
| DE (1) | DE602006009656D1 (es) |
| DK (1) | DK1898904T3 (es) |
| EC (1) | ECSP077987A (es) |
| ES (2) | ES2385129T3 (es) |
| GT (1) | GT200600246A (es) |
| HK (2) | HK1117037A1 (es) |
| HR (1) | HRP20090680T1 (es) |
| IL (1) | IL187420A (es) |
| JO (1) | JO2584B1 (es) |
| MA (1) | MA29564B1 (es) |
| MX (1) | MX2007015677A (es) |
| MY (1) | MY152185A (es) |
| NO (1) | NO343043B1 (es) |
| NZ (1) | NZ563447A (es) |
| PE (3) | PE20070691A1 (es) |
| PL (2) | PL2191824T3 (es) |
| PT (2) | PT1898904E (es) |
| RU (1) | RU2423124C2 (es) |
| SA (1) | SA06270171B1 (es) |
| SI (1) | SI1898904T1 (es) |
| TN (1) | TNSN07464A1 (es) |
| TW (1) | TWI381835B (es) |
| WO (1) | WO2006135723A2 (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1894251B (zh) * | 2003-11-17 | 2011-06-29 | 默克和西伊公司 | (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型 |
| CN1918119B (zh) | 2004-02-05 | 2011-08-31 | 杏林制药株式会社 | 双环酯类衍生物 |
| CN1960992B (zh) * | 2004-06-02 | 2011-10-19 | 桑多斯股份公司 | 晶体形式的美罗培南中间体 |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| BRPI0616040A2 (pt) * | 2005-09-21 | 2011-06-07 | Nycomed Gmbh | cloridrato de sulfonilpirról como inibidor de histona desacetilases |
| WO2007053427A2 (en) * | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives |
| CA2633167A1 (en) * | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| CN101395131B (zh) | 2006-03-08 | 2012-11-14 | 杏林制药株式会社 | 氨基乙酰基吡咯烷甲腈衍生物的制备方法及其制备中间体 |
| WO2007144006A1 (en) * | 2006-06-16 | 2007-12-21 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| AU2007318132B2 (en) * | 2006-10-27 | 2012-11-08 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| ATE550319T1 (de) | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
| US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
| AR071318A1 (es) * | 2008-04-15 | 2010-06-09 | Basilea Pharmaceutica Ag | Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso |
| US8097719B2 (en) * | 2008-07-15 | 2012-01-17 | Genesen Labs | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CA2732984A1 (en) | 2008-08-07 | 2010-02-11 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
| KR101657960B1 (ko) | 2008-08-15 | 2016-09-20 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| KR20110115582A (ko) | 2009-02-13 | 2011-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제 |
| AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
| KR20120003906A (ko) * | 2009-03-27 | 2012-01-11 | 교린 세이야꾸 가부시키 가이샤 | 염기성 첨가제를 함유하는 매트릭스형 서방성 제제 |
| CN102448456A (zh) * | 2009-03-27 | 2012-05-09 | 百时美施贵宝公司 | 用dpp-iv抑制剂预防重度有害心血管事件的方法 |
| CN102573476A (zh) * | 2009-10-23 | 2012-07-11 | 默沙东公司 | 二肽基肽酶-4抑制剂与吡格列酮的复合药的药物组合物 |
| CA2782179C (en) | 2009-11-27 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| RU2545456C2 (ru) | 2010-03-12 | 2015-03-27 | Омерос Корпорейшн | Pde10 ингибиторы и содержащие их композиции и способы |
| US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
| ES2935300T3 (es) | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
| ES2953123T3 (es) | 2010-06-24 | 2023-11-08 | Boehringer Ingelheim Int | Terapia para la diabetes |
| SG188361A1 (en) * | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
| EP2468268B1 (en) | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
| TR201010683A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formülasyonları. |
| TR201101809A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
| TR201107482A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu. |
| WO2013036213A1 (en) | 2011-09-07 | 2013-03-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
| EP2572704A1 (en) | 2011-09-22 | 2013-03-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-Disintegrating Formulations of Vildagliptin |
| WO2013044816A1 (en) * | 2011-09-30 | 2013-04-04 | Sunshine Lake Pharma Co., Ltd. | Crystalline forms of azilsartan and preparation and uses thereof |
| EP2578208B1 (en) | 2011-10-06 | 2014-05-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014065427A1 (ja) * | 2012-10-26 | 2014-05-01 | 株式会社 三和化学研究所 | アナグリプチン含有固形製剤 |
| WO2015132359A1 (en) | 2014-03-06 | 2015-09-11 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Vildagliptin formulation process under inert gas atmosphere |
| NZ630803A (en) * | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| RU2585378C1 (ru) * | 2014-11-28 | 2016-05-27 | Дмитрий Сергеевич Титов | Твердая дозированная лекарственная форма для орального введения, содержащая комбинацию вилдаглиптина и гликвидона |
| AU2016250843A1 (en) | 2015-04-24 | 2017-10-12 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| RU2602688C1 (ru) * | 2015-06-29 | 2016-11-20 | Елена Николаевна Якушева | Способ моделирования состояния ингибирования функциональной активности гликопротеина-р ингибитором дипептидилпептидазы 4 |
| CA3003611C (en) | 2015-11-04 | 2022-11-01 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| MX2018007681A (es) | 2015-12-28 | 2018-11-14 | Wockhardt Ltd | Composicion farmaceutica osmotica oral de vildagliptin. |
| WO2018050892A1 (en) * | 2016-09-16 | 2018-03-22 | Galenicum Health S.L. | Vildagliptin pharmaceutical compositions |
| TWI815820B (zh) * | 2017-09-07 | 2023-09-21 | 美商Ａｔｎｘ特殊目的實體公司 | ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式 |
| BR112021024099A2 (pt) * | 2019-05-29 | 2022-01-11 | Abbott Healthcare Pvt Ltd | Composição farmacêutica para diabetes mellitus |
| JP7461735B2 (ja) * | 2019-12-02 | 2024-04-04 | 日本ジェネリック株式会社 | ビルダグリプチン含有錠剤 |
| CN111303230B (zh) * | 2020-03-09 | 2021-07-13 | 中国食品药品检定研究院 | 一种黄体酮共晶物及其制备方法和用途 |
| WO2021234430A1 (en) * | 2020-05-17 | 2021-11-25 | Lotus International Pte. Ltd. | Modified release dosage form comprising vildagliptin and process for manufacturing the same |
| CN115054582B (zh) * | 2022-08-08 | 2022-12-06 | 北京惠之衡生物科技有限公司 | 一种维格列汀片的制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| SK16412000A3 (sk) | 1998-05-11 | 2001-08-06 | Takeda Chemical Industries, Ltd. | Deriváty kyseliny oxyiminoalkánovej |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| EP1140084A1 (en) * | 1998-12-22 | 2001-10-10 | Novo Nordisk A/S | Novel formulation |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1743655B1 (en) * | 2000-01-21 | 2014-06-25 | Novartis AG | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| EP1254113A1 (en) | 2000-01-24 | 2002-11-06 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| EP2055302B1 (en) | 2000-03-31 | 2014-09-10 | Royalty Pharma Collection Trust | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| AU6895801A (en) | 2000-07-04 | 2002-01-14 | Novo Nordisk As | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
| HU227882B1 (hu) | 2000-08-10 | 2012-05-29 | Mitsubishi Tanabe Pharma Corp | Prolinszármazékok és gyógyszerként való alkalmazásuk |
| WO2002030890A1 (fr) | 2000-10-06 | 2002-04-18 | Tanabe Seiyaku Co., Ltd. | Composes azotes a noyau a cinq elements |
| GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
| PL364221A1 (en) | 2001-02-02 | 2004-12-13 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
| SI1368349T1 (sl) | 2001-02-24 | 2007-06-30 | Boehringer Ingelheim Pharma | Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| CN1723196A (zh) | 2001-06-27 | 2006-01-18 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| KR20040033048A (ko) | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | 티아졸리딘 유도체 및 이의 약학적 용도 |
| AU2002331311A1 (en) | 2001-09-19 | 2003-04-01 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| JP5105684B2 (ja) * | 2002-03-15 | 2012-12-26 | 大塚製薬株式会社 | 持続性医薬製剤 |
| JP2004123738A (ja) * | 2002-09-11 | 2004-04-22 | Takeda Chem Ind Ltd | 徐放性製剤 |
| EP1537880A4 (en) * | 2002-09-11 | 2009-07-01 | Takeda Pharmaceutical | PREPARATION FOR PROLONGED RELEASE |
| ATE390416T1 (de) | 2002-10-18 | 2008-04-15 | Merck & Co Inc | Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| CA2519208A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| JP4933033B2 (ja) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| WO2006022428A1 (ja) * | 2004-08-26 | 2006-03-02 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
| BRPI0518409A2 (pt) * | 2004-10-25 | 2008-11-18 | Novartis Ag | combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
-
2006
- 2006-06-01 MY MYPI20062526 patent/MY152185A/en unknown
- 2006-06-06 JO JO2006163A patent/JO2584B1/en active
- 2006-06-07 GT GT200600246A patent/GT200600246A/es unknown
- 2006-06-08 AT AT06772653T patent/ATE444748T1/de active
- 2006-06-08 RU RU2007148241/15A patent/RU2423124C2/ru active
- 2006-06-08 KR KR1020077028585A patent/KR101312812B1/ko active IP Right Grant
- 2006-06-08 AT AT09172285T patent/ATE549019T1/de active
- 2006-06-08 AU AU2006257947A patent/AU2006257947B2/en not_active Ceased
- 2006-06-08 EP EP06772653A patent/EP1898904B1/en active Active
- 2006-06-08 DK DK06772653T patent/DK1898904T3/da active
- 2006-06-08 MX MX2007015677A patent/MX2007015677A/es active IP Right Grant
- 2006-06-08 EP EP09172285A patent/EP2191824B1/en active Active
- 2006-06-08 NZ NZ563447A patent/NZ563447A/en not_active IP Right Cessation
- 2006-06-08 ES ES09172285T patent/ES2385129T3/es active Active
- 2006-06-08 WO PCT/US2006/022416 patent/WO2006135723A2/en active Application Filing
- 2006-06-08 DE DE602006009656T patent/DE602006009656D1/de active Active
- 2006-06-08 JP JP2008515955A patent/JP5579986B2/ja active Active
- 2006-06-08 PL PL09172285T patent/PL2191824T3/pl unknown
- 2006-06-08 AR ARP060102393A patent/AR054383A1/es unknown
- 2006-06-08 CA CA002610422A patent/CA2610422A1/en not_active Abandoned
- 2006-06-08 PT PT06772653T patent/PT1898904E/pt unknown
- 2006-06-08 US US11/916,931 patent/US20100021539A1/en not_active Abandoned
- 2006-06-08 SI SI200630500T patent/SI1898904T1/sl unknown
- 2006-06-08 ES ES06772653T patent/ES2334261T3/es active Active
- 2006-06-08 PL PL06772653T patent/PL1898904T3/pl unknown
- 2006-06-08 BR BRPI0613499A patent/BRPI0613499B8/pt active IP Right Grant
- 2006-06-08 PT PT09172285T patent/PT2191824E/pt unknown
- 2006-06-09 TW TW095120638A patent/TWI381835B/zh not_active IP Right Cessation
- 2006-06-09 PE PE2006000647A patent/PE20070691A1/es active IP Right Grant
- 2006-06-09 PE PE2015000134A patent/PE20150728A1/es not_active Application Discontinuation
- 2006-06-09 PE PE2010001149A patent/PE20110057A1/es not_active Application Discontinuation
- 2006-06-10 SA SA6270171A patent/SA06270171B1/ar unknown
-
2007
- 2007-11-15 IL IL187420A patent/IL187420A/en active IP Right Grant
- 2007-12-07 TN TNP2007000464A patent/TNSN07464A1/en unknown
- 2007-12-07 EC EC2007007987A patent/ECSP077987A/es unknown
- 2007-12-26 MA MA30508A patent/MA29564B1/fr unknown
-
2008
- 2008-01-10 NO NO20080177A patent/NO343043B1/no not_active IP Right Cessation
- 2008-06-26 HK HK08107114.8A patent/HK1117037A1/xx not_active IP Right Cessation
-
2009
- 2009-12-21 HR HR20090680T patent/HRP20090680T1/hr unknown
-
2010
- 2010-01-05 CY CY20101100020T patent/CY1109719T1/el unknown
- 2010-10-15 HK HK10109778.7A patent/HK1143094A1/xx not_active IP Right Cessation
- 2010-12-15 US US12/968,885 patent/US20110086096A1/en not_active Abandoned
-
2013
- 2013-05-24 JP JP2013110179A patent/JP2013177428A/ja not_active Withdrawn
-
2015
- 2015-01-15 JP JP2015006061A patent/JP2015091864A/ja not_active Withdrawn
-
2016
- 2016-06-15 JP JP2016119018A patent/JP2016222675A/ja not_active Withdrawn
-
2018
- 2018-06-04 JP JP2018106602A patent/JP2018172392A/ja not_active Withdrawn
-
2019
- 2019-11-13 JP JP2019205708A patent/JP2020055816A/ja not_active Withdrawn
-
2022
- 2022-01-27 JP JP2022010646A patent/JP2022058771A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090680T1 (hr) | Formulacija s modificiranim otpuštanjem 1-/(3-hidroksi-adamant-1-ilamino)-acetil/-pirolidin-2-(s)-karbonitrila | |
| KR100760430B1 (ko) | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 | |
| CA2229597C (en) | Oral fast-dissolving compositions for dopamine agonists | |
| US5338550A (en) | Stereoisomer therapy | |
| HRP20160988T1 (hr) | Farmaceutski sastavi s dvostrukim djelovanjem na temelju superstruktura od antagonista/blokatora receptora angiotenzina (arb) i neutralnih inhibitora endopeptidaze (nep) | |
| RU2006118323A (ru) | Лекарственные формы оксикодона с контролируемым высвобождением для одноразового перорального применения | |
| AU725949B2 (en) | Antithrombotic antiatherogenic pharmaceutical composition comprising a thienopyridine derivative and an HMG-CoA-reductase inhibitor | |
| KR20090097224A (ko) | 인돌릴말레이미드 유도체를 포함하는 제약 조성물 | |
| SK281441B6 (sk) | Použitie 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzotiazolu | |
| GB2447015A (en) | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone | |
| Sledge Jr et al. | Phase III double‐blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple‐day cisplatin‐based chemotherapy | |
| EP1696893A1 (en) | Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass. | |
| JP2004518734A (ja) | カルベジロールの新規処方 | |
| WO2002003975A2 (en) | Combinations of ssri and estrogenic agents | |
| CN100553630C (zh) | 用于口服二甲双胍的控释制剂 | |
| EP1413295B1 (en) | Sustained release composition for oral administration of drugs | |
| CA1263087A (en) | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions | |
| TWI681773B (zh) | 包含氨氯地平（ａｍｌｏｄｉｐｉｎｅ）及洛沙坦（ｌｏｓａｒｔａｎ）之固體藥學組成物 | |
| TWI513462B (zh) | 糖尿病之治療或預防藥 | |
| Wente et al. | Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation | |
| EP2407159B1 (en) | Pharmaceutical compositions of olmesartan | |
| NL8502178A (nl) | Nieuwe farmaceutische preparaten. | |
| EP2676661B1 (en) | Orally administered sustained-release triple-layer pill containing tamsulosin or pharmaceutically acceptable salt thereof | |
| HEDNER et al. | Chronic 5‐HT2‐Receptor Blockade by Ritanserin Does Not Reduce Blood Pressure in Patients with Essential Hypertension | |
| CZ301993B6 (cs) | Pevná galenická orální forma s prolongovaným uvolnováním molsidominu |